Bonesupport Holding AB (publ)

$ 210.60 1.15 %

Bonesupport Holding AB (publ) is an orthobiologics company that specializes in the development and commercialization of injectable bioceramic bone graft substitutes. These products are utilized for treating bone voids and are available internationally, including in Europe and North America. Among its key offerings are CERAMENT Bone Void Filler, a synthetic, injectable, moldable, and drillable solution comprising hydroxyapatite, calcium sulfate, and the radio-contrast agent iohexol. Additionally, the company provides CERAMENT G, an injectable ceramic bone graft substitute infused with gentamicin, and CERAMENT V, a synthetic bone void filler containing vancomycin. Bonesupport is also advancing preclinical product candidates focused on promoting bone regrowth. These future solutions are being developed for applications such as trauma, revision arthroplasty, chronic osteomyelitis, oncology, and bone and foot infections related to diabetes. Founded in 1999, the company maintains its headquarters in Lund, Sweden.

CEO: Torbjorn Skold - https://www.bonesupport.com

Price objectif

-

Recommandation

-

DCF

$ -346.96

Loading data...

BONEX.ST vs S&P500

Loading data...

No data available.

Quick ratio

4.23

suggests a healthy liquidity position, showing that the company can likely meet its short-term obligations.

P/E ratio

75.76

is considered reasonable, suggesting that the company has a valuation in line with its current profits.

EPS

2.78

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

21.53 %

is generally considered excellent, indicating that the company is generating strong profits with its equity.

ROIC

21.01 %

generates a return higher than the cost of its capital, thereby creating value for its investors.

WACC

6.49

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

0.02

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

3.73

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

0.00 %

the dividend payout ratio is the measure of dividends paid out to shareholders relative to the company's net income.

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
5 indicates moderate financial health
Altman score
48.07 indicates good financial health and low risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
2.62 indicates that the company has sufficient cash to cover its short-term debts
Debt Ratio
0.01 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.